Prediction of Late Disease Recurrence by H/I BiomarkerPrediction of Late Disease Recurrence by H/I Biomarker

A biomarker identifies ER-positive patients who are at risk for late disease recurrence after tamoxifen therapy, and those who would benefit from extended endocrine therapy with letrozole. Journal of the National Cancer Institute
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news